(Q56893551)

https://api.crossref.org/works/10.1586%2FERV.11.120

Severe respiratory syncytial virus disease in Alaska native children. RSV Alaska Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

Viral and host factors in human respiratory syncytial virus pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

The burden of respiratory syncytial virus infection in young children

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

Challenges in developing a pediatric RSV vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

Biological challenges and technological opportunities for respiratory syncytial virus vaccine development

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

Bronchiolitis-associated mortality and estimates of respiratory syncytial virus-associated deaths among US children, 1979-1997.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

Bronchiolitis-associated hospitalizations among US children, 1980-1996.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

Respiratory syncytial virus and parainfluenza virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

Relative impact of influenza and respiratory syncytial virus in young children

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

Rates of hospitalization for respiratory syncytial virus infection among children in medicaid

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

Correlates of immunity to respiratory syncytial virus (RSV) associated-hospitalization: establishment of minimum protective threshold levels of serum neutralizing antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

Seasonal variation of maternally derived respiratory syncytial virus antibodies and association with infant hospitalizations for respiratory syncytial virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

Risk of respiratory syncytial virus infection for infants from low-income families in relationship to age, sex, ethnic group, and maternal antibody level

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

Risk factors for severe respiratory syncytial virus disease in children with cancer: the importance of lymphopenia and young age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

Respiratory syncytial virus infection in elderly and high-risk adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

Risk factors for respiratory failure associated with respiratory syncytial virus infection in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

Community respiratory virus infections in immunocompromised patients: hematopoietic stem cell and solid organ transplant recipients, and individuals with human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

Community respiratory viruses in individuals with human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

The effect of respiratory syncytial virus on subsequent recurrent wheezing in atopic and nonatopic children

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

The role of respiratory virus infections in childhood asthma inception

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

Immunity to and frequency of reinfection with respiratory syncytial virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

A randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

Reduction of respiratory syncytial virus (RSV) in tracheal aspirates in intubated infants by use of humanized monoclonal antibody to RSV F protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

Palivizumab prophylaxis, respiratory syncytial virus, and subsequent recurrent wheezing

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

Structure and ion channel activity of the human respiratory syncytial virus (hRSV) small hydrophobic protein transmembrane domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

The secreted form of respiratory syncytial virus G glycoprotein helps the virus evade antibody-mediated restriction of replication by acting as an antigen decoy and through effects on Fc receptor-bearing leukocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

Paramyxovirus fusion (F) protein: a conformational change on cleavage activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

The structural basis of paramyxovirus invasion

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

Pattern recognition receptors TLR4 and CD14 mediate response to respiratory syncytial virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

New insights for development of a safe and protective RSV vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

Respiratory syncytial virus nonstructural proteins NS1 and NS2 mediate inhibition of Stat2 expression and alpha/beta interferon responsiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

Small interfering RNA profiling reveals key role of clathrin-mediated endocytosis and early endosome formation for infection by respiratory syncytial virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

Macrophage dysfunction and susceptibility to pulmonary Pseudomonas aeruginosa infection in surfactant protein C-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

The fusion glycoprotein of human respiratory syncytial virus facilitates virus attachment and infectivity via an interaction with cellular heparan sulfate

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

Respiratory syncytial virus with the fusion protein as its only viral glycoprotein is less dependent on cellular glycosaminoglycans for attachment than complete virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

Glycosaminoglycan sulfation requirements for respiratory syncytial virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

Blocking intercellular adhesion molecule-1 on human epithelial cells decreases respiratory syncytial virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

CX3C chemokine mimicry by respiratory syncytial virus G glycoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

Protective efficacy, immunotherapeutic potential, and safety of hepatitis B vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

Development of a synthetic consensus sequence scrambled antigen HIV-1 vaccine designed for global use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

Cutting Edge: Long-Term B Cell Memory in Humans after Smallpox Vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

Immunity and immunological memory following smallpox vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

Humoral immunity due to long-lived plasma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

Genetic control of immune responses in vitro. I. Development of primary and secondary plaque-forming cell responses to the random terpolymer 1-glutamic acid 60-1-alanine30-1-tyrosine10 (GAT) by mouse spleen cells in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

Phenotypes and functions of persistent Sendai virus-induced antibody forming cells and CD8+ T cells in diffuse nasal-associated lymphoid tissue typify lymphocyte responses of the gut

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

Robust IgA and IgG-producing antibody forming cells in the diffuse-NALT and lungs of Sendai virus-vaccinated cotton rats associate with rapid protection against human parainfluenza virus-type 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) compared to the licensed 7vCRM vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

The new pentavalent rotavirus vaccine composed of bovine (strain WC3) -human rotavirus reassortants

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

Antibodies mediate intracellular immunity through tripartite motif-containing 21 (TRIM21)

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

Fc receptor-mediated antiviral antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

Novel mechanism of antibodies to hepatitis B virus in blocking viral particle release from cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

FcRn-mediated antibody transport across epithelial cells revealed by electron tomography

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

Safety and immunogenicity of palivizumab (Synagis) administered for two seasons

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

Humoral and mucosal immunity in protection from natural respiratory syncytial virus infection in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

Comparison of antibody concentrations and protective activity of respiratory syncytial virus immune globulin and conventional immune globulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

CD4+ T cells are required for the maintenance, not programming, of memory CD8+ T cells after acute infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

Developing and maintaining protective CD8+ memory T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

A recombinant Sendai virus is controlled by CD4+ effector T cells responding to a secreted human immunodeficiency virus type 1 envelope glycoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

Clearance of HIV type 1 envelope recombinant sendai virus depends on CD4+ T cells and interferon-gamma but not B cells, CD8+ T cells, or perforin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

Defective antigen processing in GILT-free mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

PAProC: a prediction algorithm for proteasomal cleavages available on the WWW.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

TCR revision generates functional CD4+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

Rearrangement of mouse immunoglobulin kappa deleting element recombining sequence promotes immune tolerance and lambda B cell production

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

T cell tolerance by clonal elimination in the thymus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

The T-cell repertoire is heavily influenced by tolerance to polymorphic self-antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

Self-tolerance eliminates T cells specific for Mls-modified products of the major histocompatibility complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

Th1 and Th2 subsets: paradigms lost?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

Mitogen- and IL-4-regulated expression of germ-line Ig gamma 2b transcripts: evidence for directed heavy chain class switching

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

Chlamydia pneumoniae infection induced allergic airway sensitization is controlled by regulatory T-cells and plasmacytoid dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

Regulatory T cells and immune tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

Natural regulatory T cells in infectious disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

The biological functions of T helper 17 cell effector cytokines in inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

Cutting edge: Th17 and regulatory T cell dynamics and the regulation by IL-2 in the tumor microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

Peripheral CD4+ T-cell differentiation regulated by networks of cytokines and transcription factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

Cross-presentation, dendritic cell subsets, and the generation of immunity to cellular antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

On cross-priming of MHC class I-specific CTL: rule or exception?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

Cellular mechanisms governing cross-presentation of exogenous antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

Recombinant bovine/human parainfluenza virus type 3 (B/HPIV3) expressing the respiratory syncytial virus (RSV) G and F proteins can be used to achieve simultaneous mucosal immunization against RSV and HPIV3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

The cotton rat provides a useful small-animal model for the study of influenza virus pathogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

The cotton rat model of respiratory viral infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

Evaluation of BBG2Na in infant macaques: specific immune responses after vaccination and RSV challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

Parainfluenza virus type 3 expressing the native or soluble fusion (F) Protein of Respiratory Syncytial Virus (RSV) confers protection from RSV infection in African green monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

Evaluation of two live, cold-passaged, temperature-sensitive respiratory syncytial virus vaccines in chimpanzees and in human adults, infants, and children

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

Growth of respiratory syncytial virus in primary epithelial cells from the human respiratory tract

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

A 3-D well-differentiated model of pediatric bronchial epithelium demonstrates unstimulated morphological differences between asthmatic and nonasthmatic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

Lung epithelial apoptosis in influenza virus pneumonia: the role of macrophage-expressed TNF-related apoptosis-inducing ligand

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

Respiratory virus immunization. I. A field trial of two inactivated respiratory virus vaccines; an aqueous trivalent parainfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

A role for immune complexes in enhanced respiratory syncytial virus disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

Persistent activation of an innate immune response translates respiratory viral infection into chronic lung disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

Antibody affinity maturation and respiratory syncytial virus disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

Involvement of toll-like receptor 4 in innate immunity to respiratory syncytial virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

Common human Toll-like receptor 4 polymorphisms--role in susceptibility to respiratory syncytial virus infection and functional immunological relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

Association between common Toll-like receptor 4 mutations and severe respiratory syncytial virus disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

Role of T lymphocyte subsets in the pathogenesis of primary infection and rechallenge with respiratory syncytial virus in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

Virus-specific CD8+ T lymphocytes downregulate T helper cell type 2 cytokine secretion and pulmonary eosinophilia during experimental murine respiratory syncytial virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

Immunopathology in RSV infection is mediated by a discrete oligoclonal subset of antigen-specific CD4(+) T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

Vbeta14(+) T cells mediate the vaccine-enhanced disease induced by immunization with respiratory syncytial virus (RSV) G glycoprotein but not with formalin-inactivated RSV

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

The immune response to respiratory syncytial virus infection: friend or foe?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

Cytokines in severe respiratory syncytial virus bronchiolitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

Macrophage inflammatory protein-1alpha (not T helper type 2 cytokines) is associated with severe forms of respiratory syncytial virus bronchiolitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

The TLR4 agonist, monophosphoryl lipid A, attenuates the cytokine storm associated with respiratory syncytial virus vaccine-enhanced disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

Enhanced pulmonary immunopathology following neonatal priming with formalin-inactivated respiratory syncytial virus but not with the BBG2NA vaccine candidate

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

Cellular response to respiratory viruses with particular reference to children with disorders of cell-mediated immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

Respiratory viruses and eosinophils: exploring the connections.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

Eosinophils contribute to innate antiviral immunity and promote clearance of respiratory syncytial virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

Pulmonary eosinophilia is attenuated by early responding CD8(+) memory T cells in a murine model of RSV vaccine-enhanced disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

CD25+ natural regulatory T cells are critical in limiting innate and adaptive immunity and resolving disease following respiratory syncytial virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

Prophylactic treatment with a G glycoprotein monoclonal antibody reduces pulmonary inflammation in respiratory syncytial virus (RSV)-challenged naive and formalin-inactivated RSV-immunized BALB/c mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

Immunomodulation with IL-4R alpha antisense oligonucleotide prevents respiratory syncytial virus-mediated pulmonary disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

The immunogenicity, protective efficacy and safety of BBG2Na, a subunit respiratory syncytial virus (RSV) vaccine candidate, against RSV-B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

Influence of administration dose and route on the immunogenicity and protective efficacy of BBG2Na, a recombinant respiratory syncytial virus subunit vaccine candidate

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

A novel bipolar mode of attachment to aluminium-containing adjuvants by BBG2Na, a recombinant subunit hRSV vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

Induction of protective immunity in rodents by vaccination with a prokaryotically expressed recombinant fusion protein containing a respiratory syncytial virus G protein fragment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

Safety and immunogenicity of a novel recombinant subunit respiratory syncytial virus vaccine (BBG2Na) in healthy young adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

Progress in the development of respiratory syncytial virus and parainfluenza virus vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

Efficacy and safety studies of a recombinant chimeric respiratory syncytial virus FG glycoprotein vaccine in cotton rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

Safety and immunogenicity of a purified F protein respiratory syncytial virus (PFP-2) vaccine in seropositive children with bronchopulmonary dysplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

Respiratory syncytial virus vaccine: a systematic overview with emphasis on respiratory syncytial virus subunit vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

Vaccination of cotton rats with a chimeric FG glycoprotein of human respiratory syncytial virus induces minimal pulmonary pathology on challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

Induction of local and systemic immunity against human respiratory syncytial virus using a chimeric FG glycoprotein and cholera toxin B subunit

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

Protection of cotton rats against human respiratory syncytial virus by vaccination with a novel chimeric FG glycoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

Evaluation of the live attenuated cpts 248/404 RSV vaccine in combination with a subunit RSV vaccine (PFP-2) in healthy young and older adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

Immunogenicity of a new purified fusion protein vaccine to respiratory syncytial virus: a multi-center trial in children with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

Purified fusion protein vaccine protects against lower respiratory tract illness during respiratory syncytial virus season in children with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

Comparison of the safety and immunogenicity of 2 respiratory syncytial virus (rsv) vaccines--nonadjuvanted vaccine or vaccine adjuvanted with alum--given concomitantly with influenza vaccine to high-risk elderly individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

Safety and immunogenicity of respiratory syncytial virus purified fusion protein-2 vaccine in pregnant women

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

Structural basis for immunization with postfusion respiratory syncytial virus fusion F glycoprotein (RSV F) to elicit high neutralizing antibody titers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

A dose-ranging study of a subunit Respiratory Syncytial Virus subtype A vaccine with and without aluminum phosphate adjuvantation in adults > or =65 years of age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

Structural basis of respiratory syncytial virus neutralization by motavizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

Structure of a Major Antigenic Site on the Respiratory Syncytial Virus Fusion Glycoprotein in Complex with Neutralizing Antibody 101F

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

Prospects for defined epitope vaccines for respiratory syncytial virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

Elicitation of structure-specific antibodies by epitope scaffolds

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

Epitope insertion into variable loops of HIV-1 gp120 as a potential means to improve immunogenicity of viral envelope protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

Structural features of HIV envelope defined by antibody escape mutant analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

Antigenic structure of influenza virus haemagglutinin defined by hybridoma antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

Antigenic and biological characterization of influenza virus neuraminidase (N2) with monoclonal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

Target peptide sequence within infectious human immunodeficiency virus type 1 does not ensure envelope-specific T-helper cell reactivation: influences of cysteine protease and gamma interferon-induced thiol reductase activities

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

Modulation of the immunogenicity of antigenic determinants by their flanking residues.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

Localization of CD4+ T cell epitope hotspots to exposed strands of HIV envelope glycoprotein suggests structural influences on antigen processing

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

Programming the magnitude and persistence of antibody responses with innate immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

Nanoparticle vaccines against respiratory viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

Evaluation of a live, cold-passaged, temperature-sensitive, respiratory syncytial virus vaccine candidate in infancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

Codon stabilization analysis of the "248" temperature sensitive mutation for increased phenotypic stability of respiratory syncytial virus vaccine candidates

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

Evaluation of recombinant respiratory syncytial virus gene deletion mutants in African green monkeys for their potential as live attenuated vaccine candidates

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

A highly attenuated recombinant human respiratory syncytial virus lacking the G protein induces long-lasting protection in cotton rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

Lipopeptide-adjuvanted respiratory syncytial virus virosomes: A safe and immunogenic non-replicating vaccine formulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

Chimeric bovine respiratory syncytial virus with glycoprotein gene substitutions from human respiratory syncytial virus (HRSV): effects on host range and evaluation as a live-attenuated HRSV vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

Protection against respiratory syncytial virus by a recombinant Newcastle disease virus vector

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

Assembly and immunological properties of Newcastle disease virus-like particles containing the respiratory syncytial virus F and G proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

Newcastle disease virus-like particles containing respiratory syncytial virus G protein induced protection in BALB/c mice, with no evidence of immunopathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

Development of a PIV-vectored RSV vaccine: preclinical evaluation of safety, toxicity, and enhanced disease and initial clinical testing in healthy adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

Human parainfluenza virus type 1 but not Sendai virus replicates in human respiratory cells despite IFN treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

Human PIV-2 recombinant Sendai virus (rSeV) elicits durable immunity and combines with two additional rSeVs to protect against hPIV-1, hPIV-2, hPIV-3, and RSV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

Recombinant Sendai virus as a novel vaccine candidate for respiratory syncytial virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

Respiratory syncytial virus (RSV) fusion protein expressed by recombinant Sendai virus elicits B-cell and T-cell responses in cotton rats and confers protection against RSV subtypes A and B

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

Sendai virus recombinant vaccine expressing hPIV-3 HN or F elicits protective immunity and combines with a second recombinant to prevent hPIV-1, hPIV-3 and RSV infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

Recombinant Sendai virus expressing the G glycoprotein of respiratory syncytial virus (RSV) elicits immune protection against RSV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

Safety and immunogenicity of intranasal murine parainfluenza virus type 1 (Sendai virus) in healthy human adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

Intranasal Sendai virus vaccine protects African green monkeys from infection with human parainfluenza virus-type one.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

Evaluation in chimpanzees of vaccinia virus recombinants that express the surface glycoproteins of human respiratory syncytial virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

US military smallpox vaccination program experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

Electrocardiography screening for cardiotoxicity after modified Vaccinia Ankara vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

Recombinant Modified Vaccinia Ankara (MVA) effectively boosts DNA-primed HIV-specific immune responses in humans despite pre-existing vaccinia immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in healthy adults in South Africa

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

A chemically defined production process for highly attenuated poxviruses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

Plasmid DNA encoding the respiratory syncytial virus G protein is a promising vaccine candidate

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

DNA immunization against respiratory syncytial virus (RSV) in infant rhesus monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

RSV fusion (F) protein DNA vaccine provides partial protection against viral infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

Mucosal delivery of human papillomavirus pseudovirus-encapsidated plasmids improves the potency of DNA vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

Gene gun particle-mediated vaccination with plasmid DNA confers protective immunity against rabies virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

Screening of HIV-1 Env glycoproteins for the ability to raise neutralizing antibody using DNA immunization and recombinant vaccinia virus boosting

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

Heterologous Prime-Boost HIV-1 Vaccination Regimens in Pre-Clinical and Clinical Trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

Age dependence of adenovirus-specific neutralizing antibody titers in individuals from sub-Saharan Africa

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

Novel, chimpanzee serotype 68-based adenoviral vaccine carrier for induction of antibodies to a transgene product

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

Single mucosal immunization of recombinant adenovirus-based vaccine expressing F1 protein fragment induces protective mucosal immunity against respiratory syncytial virus infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

A new generation of animal cell expression vectors based on the Semliki Forest virus replicon

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

Recombinant alphaviruses as vectors for anti-tumour and anti-microbial immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

Venezuelan equine encephalitis virus replicon particles encoding respiratory syncytial virus surface glycoproteins induce protective mucosal responses in mice and cotton rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

Efficient lung recruitment of respiratory syncytial virus-specific Th1 cells induced by recombinant bacillus Calmette-Guérin promotes virus clearance and protects from infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

Oral respiratory syncytial virus (RSV) DNA vaccine expressing RSV F protein delivered by attenuated Salmonella typhimurium

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

Systemic and mucosal immunity to respiratory syncytial virus induced by recombinant Streptococcus gordonii surface-displaying a domain of viral glycoprotein G.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

Transgenic apple expressing an antigenic protein of the human respiratory syncytial virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

Tumor infiltrating lymphocyte therapy for metastatic melanoma: analysis of tumors resected for TIL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

Clinical practice. Prevention of meningococcal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

A prime-boost vaccination strategy using attenuated Salmonella typhimurium and a replication-deficient recombinant adenovirus vector elicits protective immunity against human respiratory syncytial virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

Low-dose intradermal administration of recombinant hepatitis B vaccine in children: 5-year follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

Trends in early childhood vaccination coverage: progress towards US Healthy People 2010 goals

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

Mortality benefits of influenza vaccination in elderly people: an ongoing controversy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

Is clinical recognition of respiratory syncytial virus infection in hospitalized elderly and high-risk adults possible?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.120

Outpatient RSV lower respiratory infections among high-risk infants and other pediatric populations

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3255794

B cell lineage contributions to antiviral host responses.

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3255794

CD8 T cells inhibit respiratory syncytial virus (RSV) vaccine-enhanced disease.

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3255794

Association of TLR4 polymorphisms with symptomatic respiratory syncytial virus infection in high-risk infants and young children

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3255794

TLR-4 and CD14 polymorphisms in respiratory syncytial virus associated disease

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3255794

Ribavirin for respiratory syncytial virus infection of the lower respiratory tract in infants and young children

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3255794

Alveolar epithelial cells direct monocyte transepithelial migration upon influenza virus infection: impact of chemokines and adhesion molecules

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3255794

Advances in respiratory syncytial virus vaccine development.

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3255794

Smallpox vaccination and adverse reactions. Guidance for clinicians.

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3255794

Association of cytokine responses with disease severity in infants with respiratory syncytial virus infection

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3255794

Vaccination with recombinant alphavirus or immune-stimulating complex antigen against respiratory syncytial virus

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3255794

The majority of immunogenic epitopes generate CD4+ T cells that are dependent on MHC class II-bound peptide-flanking residues

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3255794

Vaccine-enhanced respiratory syncytial virus disease in cotton rats following immunization with Lot 100 or a newly prepared reference vaccine

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3255794

Immune induction and modulation in mice following immunization with DNA encoding F protein of respiratory syncytial virus

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3255794

Furin cleavage of the respiratory syncytial virus fusion protein is not a requirement for its transport to the surface of virus-infected cells

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3255794

Pulmonary collectins and innate host defense of the lung

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3255794

Microbial lipopeptides induce the production of IL-17 in Th cells.

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3255794

Type 1-like immune response is found in children with respiratory syncytial virus infection regardless of clinical severity

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3255794

DNA encoding the attachment (G) or fusion (F) protein of respiratory syncytial virus induces protection in the absence of pulmonary inflammation

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3255794

Paramyxovirus reverse genetics is coming of age.

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3255794

Uncovering subdominant cytotoxic T-lymphocyte responses in lymphocytic choriomeningitis virus-infected BALB/c mice.

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3255794

Differential dependence on target site tissue for gene gun and intramuscular DNA immunizations

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3255794

Respiratory syncytial virus illnesses in human immunodeficiency virus- and noninfected children

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3255794

The membrane-associated and secreted forms of the respiratory syncytial virus attachment glycoprotein G are synthesized from alternative initiation codons

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3255794

Respiratory virus infection of mice provokes a permanent humoral immune response

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3255794

Enhanced pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV-immunized BALB/c mice is abrogated by depletion of interleukin-4 (IL-4) and IL-10.

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3255794

Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3255794

Field evaluation of a respiratory syncytial virus vaccine and a trivalent parainfluenza virus vaccine in a pediatric population

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3255794

Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3255794

An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3255794

Quantitative aspects of passive immunity to respiratory syncytial virus infection in infant cotton rats

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3255794

Dissociation between serum neutralizing and glycoprotein antibody responses of infants and children who received inactivated respiratory syncytial virus vaccine

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3255794

Effectiveness of topically administered neutralizing antibodies in experimental immunotherapy of respiratory syncytial virus infection in cotton rats.

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3255794

Further characterization of the soluble form of the G glycoprotein of respiratory syncytial virus

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3255794

Passive transfer of respiratory syncytial virus (RSV) antiserum suppresses the immune response to the RSV fusion (F) and large (G) glycoproteins expressed by recombinant vaccinia viruses

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3255794

Formalin-inactivated respiratory syncytial virus vaccine induces antibodies to the fusion glycoprotein that are deficient in fusion-inhibiting activity.

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3255794

Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3255794

Complication of intramuscular/subcutaneous immune therapy in severely immune-compromised individuals

2 November 2018

1 reference

12 December 2020

Activation of antigen-specific T cell-responses by mannan-decorated PLGA nanoparticles

1 reference

12 December 2020

AIDS vaccines. HIV dodges one-two punch

1 reference

12 December 2020

A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes

1 reference

12 December 2020

Viral Respiratory Infections in the Institutionalized Elderly: Clinical and Epidemiologic Findings

1 reference

12 December 2020

The impact of prophylaxis on paediatric intensive care unit admissions for RSV infection: a retrospective, single-centre study

1 reference

12 December 2020

CD4+CD25+ regulatory T cells control innate immune reactivity after injury

1 reference

12 December 2020

Genetic Control of the Antibody Response: Relationship between Immune Response and Histocompatibility (H-2) Type

1 reference

12 December 2020

A mouse T cell product that preferentially enhances IgA production. I. Biologic characterization

1 reference

12 December 2020

AIDS vaccine therapy: phase I trial

1 reference

12 December 2020